Related Experiment Video
Updated: Dec 29, 2025
04:37
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
598
Financial incentives for hypertension control: rationale and study design
Liqiang Zheng1, Yali Wang2, Sitong Liu2
1Department of Cardiology, Department of Library and Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China. liqiangzheng@126.com.
Trials
|February 5, 2020
Summary
Financial incentives may improve hypertension control in China. This study tested if incentives, combined with mobile health management, reduce blood pressure (BP) more effectively than mobile management alone in hypertensive patients.
Area of Science:
- Cardiovascular Medicine
- Public Health
- Behavioral Economics
Background:
- Lifestyle modifications and antihypertensive medications are effective but adherence is low.
- Behavioral economic incentive approaches show promise for improving treatment adherence.
- Hypertension control remains a significant public health challenge in China.
Purpose of the Study:
- To evaluate the effectiveness of financial incentives in reducing blood pressure (BP) among hypertensive patients in China.
- To assess the impact of incentives on hypertension control and adherence to treatment.
- To determine the cost-effectiveness of financial incentive programs for hypertension management.
Main Methods:
- A multicenter, randomized controlled trial involving 400 participants in China.
- Two parallel arms: control group (mobile management) and intervention group (mobile management + financial incentives).
- Primary outcome: net change in systolic blood pressure (SBP) at 12 months. Secondary outcomes include diastolic BP, BP control, adherence, and cost-effectiveness.
Main Results:
- This section is not available in the provided abstract.
- Further analysis is required to determine the specific outcomes.
- The study is designed to generate robust data on the efficacy of financial incentives.
Conclusions:
- This trial will determine if financial incentives improve hypertension control in China.
- The findings will provide data for optimizing hypertension and cardiovascular disease management strategies.
- The study addresses the gap in popularizing treatment benefits among the general public.
Related Concept Videos
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
382
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
382
01:23Hypertension V: Nursing Management
299
The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
299
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
500
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
500
01:29Hypertension II: Pathophysiology
637
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
637
01:28Hypertension I: Introduction
594
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
594
01:18Hypertension and Regulation of Blood Pressure
3.6K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.6K